BMRN · XBRL financial data

BioMarin Pharmaceutical financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (BMRN's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	1,860	1,846	2,096	2,419	2,854	3,221
Cost of revenue	524	471	484	515	580	717
Research and development	628	629	650	747	747	922
Selling, general and administrative	738	759	854	937	1,009	1,153
Other operating income (expense)	7	12	(2)	(11)	(5)	9
Operating income (loss)	(37)	(82)	150	158	484	409
Interest income	17	10	18	58	75	75
Interest expense	29	15	16	17	13	11
Income tax expense (benefit)	(901)	(11)	8	21	115	134
Net income (loss)	859	(64)	142	168	427	349
Earnings per share, basic USD per share	4.75	(0.35)	0.76	0.89	2.25	1.82
Earnings per share, diluted USD per share	4.53	(0.35)	0.75	0.87	2.21	1.80
Weighted average shares, basic millions of shares	181	183	185	188	190	192
Weighted average shares, diluted millions of shares	192	183	189	192	197	197

Fiscal years (BMRN's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	649	587	725	755	943	1,312
Marketable securities	416	427	567	319	195	249
Marketable securities, non-current	285	508	334	611	521	492
Accounts receivable	448	373	461	634	661	908
Inventory	699	777	894	1,107	1,233	1,299
Total current assets	2,342	2,274	2,751	2,956	3,232	3,953
Property and equipment, net	1,032	1,035	1,073	1,066	1,043	953
Right-of-use asset	46	38	35	43	29	35
Goodwill	196	196	196	196	196	196
Total assets	5,848	6,003	6,375	6,842	6,989	7,594
Accounts payable	—	—	—	—	—	31
Current portion of long-term debt	—	—	—	—	—	0
Total current liabilities	493	540	589	1,177	607	759
Long-term debt	—	—	—	—	—	597
Lease liability, non-current	40	32	26	38	31	37
Total liabilities	1,742	1,733	1,772	1,890	1,331	1,507
Retained earnings (accumulated deficit)	(862)	(926)	(789)	(622)	(195)	154
Total stockholders' equity	4,106	4,271	4,603	4,952	5,658	6,087
Total liabilities and equity	5,848	6,003	6,375	6,842	6,989	7,594
Common shares outstanding (cover page) millions of shares	182	184	187	189	191	192

Fiscal years (BMRN's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	859	(64)	142	168	427	349
Stock-based compensation	190	197	196	207	202	181
Depreciation and amortization	105	108	102	104	96	80
Net cash from operating activities	85	305	176	159	573	828
Purchases of property and equipment	114	96	121	97	85	103
Net cash from investing activities	(54)	(366)	(20)	(111)	136	(414)
Share repurchases	50	0	0	—	—	—
Net cash from financing activities	181	(0)	(19)	(19)	(526)	(42)
Net change in cash	212	(62)	137	31	188	369

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Biomarin Pharmaceutical	874	990	168*	193.6M	—	Q2 FY26 10-QJun 30, 2026
Revolution Medicines	815	not reported	(387)*	214.3M	10.2 quarters	Q2 FY26 10-QJun 30, 2026
Jazz Pharmaceuticals	2,036	1,243	506*	64.2M	—	Q3 FY26 10-QSep 30, 2026
Corcept Therapeutics	99	340	143*	109.4M	—	Q3 FY26 10-QSep 30, 2026
Repligen	727	209	43*	63.9M	—	Q3 FY26 10-QSep 30, 2026
Madrigal Pharmaceuticals	515	431	121*	23.2M	—	Q3 FY26 10-QSep 30, 2026
Ionis Pharmaceuticals	350	268	566*	166.2M	—	Q2 FY26 10-QJun 30, 2026
BIO-TECHNE	265	321*	95*	156.8M	—	Q4 FY26 10-KJun 30, 2026
Exelixis	305	659	280*	244.0M	—	Q3 FY26 10-QOct 2, 2026

Not investment advice. Not affiliated with the U.S. SEC.